Drug Targets & Biological Macromolecules

protein–protein interaction

A protein–protein interaction is the contact between two proteins that lets them work together, like two puzzle pieces clicking into place. Cells run on these handshakes: signals are passed, machines are assembled, and decisions are made when the right proteins touch. Interrupting a harmful handshake is an appealing way to treat disease.

Unlike an enzyme's compact active site, the interface where two proteins meet is often large, flat, and spread out, with no deep pocket for a small molecule to grab. This makes many such interfaces hard to drug with conventional small molecules, which historically led people to call them undruggable. Progress came from finding small hotspots on the interface that contribute most of the binding energy.

Modern medicinal chemistry tackles these targets with several strategies, including molecules that wedge into a hotspot, larger ring-shaped compounds, peptides, and degraders that recruit the cell's disposal system. The honest caveat is that protein–protein interactions remain among the most challenging targets, and success is still the exception rather than the rule.

Venetoclax treats leukemia by wedging into the interaction between the survival protein BCL-2 and its partners, freeing cancer cells to undergo programmed death.

Disrupting a protein handshake can release a cell from a harmful command.

Targeting a protein–protein interaction often means stabilizing a contact rather than breaking it, as molecular glues do by gluing two proteins together.

Also called
PPI蛋白相互作用蛋白交互作用